Reported Sunday, AstraZeneca's DATROWAY Shows Over 55% Response Rate In First-Line Advanced NSCLC In TROPION-Lung02 Phase 1b Trial With Immunotherapy Combinations

-0.15% Post

-1.02% Post

Astrazeneca PLC Sponsored ADR

AZN

0.00

DAIICHI SANKYO COMPANY LIMITED

DSNKY

0.00

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC
TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting
NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.